ASKA Pharmaceutical Holdings Co (TSE:4886) EBIT : 円9,902 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co EBIT?

ASKA Pharmaceutical Holdings Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was 円3,120 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was 円9,902 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ASKA Pharmaceutical Holdings Co's annualized ROC % for the quarter that ended in Dec. 2023 was 11.01%. ASKA Pharmaceutical Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 37.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 17.74%.

ASKA Pharmaceutical Holdings Co EBIT Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co EBIT Chart

ASKA Pharmaceutical Holdings Co Annual Data

Trend

Mar22

Mar23

Mar24

EBIT

6,219.00

5,407.00

9,902.00

ASKA Pharmaceutical Holdings Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial							2.00	1,884.00	3,547.00	3,120.00	1,351.00

Competitive Comparison of ASKA Pharmaceutical Holdings Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ASKA Pharmaceutical Holdings Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's EV-to-EBIT falls into.

ASKA Pharmaceutical Holdings Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円9,902 Mil.

ASKA Pharmaceutical Holdings Co (TSE:4886) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ASKA Pharmaceutical Holdings Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	9884 * ( 1 - 25.14% )	/	( (66206	+	68165)	/ 2 )
=	7399.1624	/	67185.5
=	11.01 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	91920	-	5368	-	( 20346	-	max(0, 20036	-	59644	+	20346	))
=	66206

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	94857	-	6338	-	( 20354	-	max(0, 21520	-	61959	+	20354	))
=	68165

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

ASKA Pharmaceutical Holdings Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	12480	/	( ( (10649 + max(22242, 0))	+	(10594 + max(23265, 0)) )	/	2 )
=	12480	/	( ( 32891	+	33859 )	/	2 )
=	12480	/	33375
=	37.39 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(17343	+	18586	+	3369)	-	(5368	+	0	+	11688)
=	22242

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(18307	+	19713	+	3585)	-	(6338	+	0	+	12002)
=	23265

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ASKA Pharmaceutical Holdings Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	9902	/	55817.819
	=	17.74 %

ASKA Pharmaceutical Holdings Co EBIT Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532

Website

https://www.aska-pharma-hd.co.jp

ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines